Reuters logo
BRIEF-Clearside Biomedical says realignment for Axitinib for treatment of wet AMD towards DME program
2017年2月27日 / 下午1点37分 / 7 个月前

BRIEF-Clearside Biomedical says realignment for Axitinib for treatment of wet AMD towards DME program

Feb 27 (Reuters) - Clearside Biomedical Inc

* Initiated strategic realignment of research and development resources from pre-clinical Axitinib development program to DME clinical development program

* Realignment for Axitinib for treatment of wet AMD toward ongoing clinical development program for dme

* No longer expects to submit an investigational new drug application to U.S. Food and drug administration for axitinib

* trial results from other participants led co to reconsider viability of further development of proprietary suspension formulation of Axitinib

* Says plans to continue to investigate Axitinib and other compounds for treatment of wet AMD

* Clearside will shift research and development resources away from wet AMD towards its DME program Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below